Varenicline versus nicotine replacement therapy for long-term smoking cessation: an observational study using the Clinical Practice Research Datalink
Background: Smoking is the leading avoidable cause of illness and premature mortality. The first-line treatments for smoking cessation are nicotine replacement therapy and varenicline. Meta-analyses of experimental studies have shown that participants allocated to the varenicline group were 1.57 tim...
Main Authors: | Neil M Davies, Amy E Taylor, Gemma MJ Taylor, Taha Itani, Tim Jones, Richard M Martin, Marcus R Munafò, Frank Windmeijer, Kyla H Thomas |
---|---|
Format: | Article |
Language: | English |
Published: |
NIHR Journals Library
2020-02-01
|
Series: | Health Technology Assessment |
Subjects: | |
Online Access: | https://doi.org/10.3310/hta24090 |
Similar Items
-
Using cost-effectiveness analysis to support policy change: varenicline and nicotine replacement therapy for smoking cessation in Jordan
by: Saba Madae’en, et al.
Published: (2020-10-01) -
Can the use of varenicline improve the efficacy of pharmacotherapy for nicotine addiction?
by: Mazur Rafał, et al.
Published: (2019-03-01) -
Tobacco smoking cessation management: integrating varenicline in current practice
by: Laurence M Galanti
Published: (2008-08-01) -
Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals
by: Edward J Mills, et al.
Published: (2010-07-01) -
Pharmacological Basis of the Clinical Efficacy of Varenicline Used to Facilitate Smoking Cessation
by: S. R. Gilyarevskiy
Published: (2019-03-01)